<DOC>
	<DOCNO>NCT00005851</DOCNO>
	<brief_summary>The reason study see cancer respond immune therapy transplantation blood stem cell ( bone marrow ) use new kind treatment regimen less toxic previously use blood stem cell transplant . This type transplant use much less chemotherapy radiation standard bone marrow transplant . The treatment consist medication weaken immune system n't reject donor 's marrow cell . Researchers hope immune cell donor attack tumor . This call `` graft versus tumor '' effect see type cancer . In addition , 65 day transplant patient may eligible immune treatment use additional immune cell donor increase effect stem cell cancer .</brief_summary>
	<brief_title>Low-Dose Total-Body Irradiation Fludarabine Phosphate Followed By Donor Peripheral Blood Stem Cell Transplant Treating Patients With Stage IV Kidney Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine whether mixed full donor hematopoietic chimerism safely establish use non-myeloablative conditioning regimen . II . To determine whether mixed chimerism safely convert full donor hematopoietic chimerism infusion donor lymphocyte ( DLI ) . III . To evaluate potential efficacy approach treatment metastatic renal cancer . OUTLINE : CONDITIONING REGIMEN : Patients receive fludarabine phosphate intravenously ( IV ) day -4 -2 undergo low-dose total-body irradiation ( TBI ) day 0 . TRANSPLANTATION : Patients undergo allogeneic peripheral blood stem cell transplant day 0 . IMMUNOSUPRESSION : Patients receive cyclosporine orally ( PO ) twice daily ( BID ) IV daily ( QD ) BID day -3 35 taper day 56 , mycophenolate mofetil PO IV 2 hour thrice daily ( TID ) day 0-40 . DLI : Patients stable mixed chimerism day 56 evidence graft-vs-host disease ( GVHD ) may receive escalate dos non-mobilized DLI 30 minute . Patients may receive 4 DLIs escalate dos disease progression evidence GVHD . After completion study treatment , patient follow periodically 5 year .</detailed_description>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients histologically confirm stage IV renal cancer stable ( include render remission ) progressive disease Human lymphocyte antigen ( HLA ) genotypically identical related donor willing undergo leukapheresis initially collection peripheral blood stem cell ( PBSC ) subsequently collection peripheral blood mononuclear cell ( PBMC ) Ionized calcium level within normal limit DONOR : HLA genotypically identical family member ( exclude identical twin ) DONOR : Donor must consent filgrastim ( GCSF ) administration leukapheresis DONOR : Donor must adequate vein leukapheresis agree placement central venous catheter ( femoral , subclavian ) DONOR : Age &lt; 75 year Patients positive serology human immunodeficiency virus ( HIV ) 1 2 , human Tlymphotropic virus ( HTLV ) 1 Patients unwilling use contraceptive technique 12 month follow treatment Serum creatinine &gt; 2.0 ; Fred Hutchinson Cancer Research Center ( FHCRC ) Patient Care Conference ( PCC ) may approve patient elevate serum creatinine follow presentation approval ; center outside FHCRC PCC equivalent obtain institutional approval ; comparable group institution , please contact FHCRC Principal Investigator FHCRC approval PCC Cardiac ejection fraction &lt; 50 % ; ejection fraction require patient history anthracyclines history cardiac disease Diffusion capacity carbon monoxide ( DLCO ) &lt; 50 % predict , total lung capacity ( TLC ) &lt; 50 % , forced expiratory volume one second ( FEV1 ) &lt; 50 % Liver function test include total bilirubin , serum glutamate pyruvate transaminase ( SGPT ) serum glutamic oxaloacetic transaminase ( SGOT ) &gt; 2 x upper limit normal unless due malignancy Karnofsky score &lt; 80 Brain metastasis Ongoing active bacterial , viral fungal infection Pregnancy breastfeeding Patients active nonhematologic malignancy ( except nonmelanoma skin cancer ) Patients history nonhematologic malignancy ( except nonmelanoma skin cancer ) currently complete remission , less 5 year time complete remission , &gt; 20 % risk disease recurrence The addition cytotoxic agent `` cytoreduction '' exception Gleevec ( imatinib mesylate ) , cytokine therapy , hydroxyurea , low dose cytarabine , chlorambucil , rituxan allow within three week initiation condition DONOR : Age le 12 year DONOR : Pregnancy DONOR : Infection HIV DONOR : Inability achieve adequate venous access DONOR : Known allergy GCSF DONOR : Current serious systemic illness DONOR : Failure meet criterion donation describe Standard Practice Guidelines institution</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>